pipeline-prospector-insert
X

Find Clinical Drug Pipeline Developments & Deals for RX-5902

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RX-5902

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Rexahn Pharmaceuticals Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination April 09, 2020

            Details:

            The company had previously disclosed that it was evaluating the development strategy for RX-5902, including whether to proceed with the trial.